Presented by Zelnez Amora, DNP, RN, CMSRN
Cancer: Abnormal, uncontrolled cell division resulting from damage to genes controlling growth.
Characteristics:
Loss of normal functions.
Rapid division.
Invasion of surrounding cells.
Metastasis: Abnormal cells traveling to other sites and establishing new tumors.
Tumor: Abnormal enlargement of tissue.
Neoplasm: Synonymous with tumor.
Benign Neoplasms:
Slow growing.
Do not metastasize.
Malignant Neoplasms:
Fast growing.
Typically metastasize, can lead to death.
Subtypes:
Sarcoma: Cancer in connective tissues.
Carcinoma: Cancer in epithelial tissues (more common).
Leukemia: Cancer in blood-forming cells in bone marrow.
Lymphoma: Cancer in lymphatic tissue.
Glioma: Cancer in glial cells of the nervous system.
Oncogenes: Mutated genes that enable cancer development by disrupting cell growth and DNA repair mechanisms, often linked to environmental factors.
Utilization of biological databases (e.g., human genome sequencing).
Identification of unique patient characteristics (genomics, cellular assays).
Ongoing research under the precision medicine initiative focusing on preventing and curing cancers (Collins & Varmus, 2015).
Cell Proliferation Responses:
Genetically altered cells proliferate abnormally.
Evade normal regulatory and immune processes.
Abnormal cell signaling leads to cancer development.
Resulting in metastasis.
Cell Characteristics
Mode of Growth
Rate of Growth
Metastasis Potential
General Effects
Tissue Destruction
Disease Causation
Malignant Transformation:
Initiation: Apoptosis of damaged cells.
Promotion: Formation of preneoplastic or benign lesions.
Progression: Involvement of angiogenesis for tumor growth.
Categories Include:
Viral and bacterial agents.
Physical agents (sunlight, radiation, chronic irritation).
Chemical agents (tobacco, asbestos).
Genetic and familial predispositions.
Lifestyle factors and hormonal influences.
Primary Prevention: Health promotion and risk reduction strategies.
Secondary Prevention: Screening and early detection of precancerous lesions.
Tertiary Prevention: Monitoring for cancer recurrence and development of secondary malignancies in survivors.
Goals of Diagnosis:
Identify presence and extent of tumors.
Evaluate possible metastasis.
Assess functions of affected and unaffected body systems.
Tissue and cellular analysis for tumor staging and grading.
Staging: Evaluates tumor size, invasion, nodal involvement, and metastasis (TNM classification).
Grading: Pathologic classification of tumor cells (grades I-IV).
Treatment specifics depend on cancer type, stage, and grade.
Goals include:
Cure
Control
Palliation
Types of Surgery:
Diagnostic surgeries (biopsy types).
Tumor removal (wide, local excisions).
Prophylactic and palliative surgeries.
Reconstructive surgery post-treatment.
Uses:
Curative, control, or palliative care.
Types:
External and Internal Radiation.
Side Effects and Reactions:
Management of toxicity and radiation reactions.
Focus on healing, comfort, and quality of life.
Assessments:
Skin integrity, nutritional status, overall well-being.
Caregiver protection measures.
Mechanism of Action: Destroys cancer cells by interfering with replication.
May be combined with other treatments (surgery, radiation).
Goals: curative, control, or palliative.
Monitoring dosages, the risk of extravasation, nadirs, and hypersensitivity reactions.
Potential toxicities include:
Gastrointestinal, Hematopoietic, Renal, Cardiopulmonary, Reproductive, Neurologic, Cognitive, and Fatigue.
No sick visitors.
Avoid plants or fresh fruits/vegetables.
Assess fluid and electrolyte status.
Monitor cognitive status.
Mitigate risks for infection and bleeding.
Administer medications and manage side effects (nausea, vomiting).
Utilized for treating various malignant and nonmalignant diseases.
Types of HSCT:
Allogeneic, Autologous, Syngeneic, Myeloablative, Nonmyeloablative.
Major cause of morbidity and mortality in allogeneic transplants.
Occurs when donor lymphocytes attack recipient tissues.
Prevention involves immunosuppressant medications (e.g., cyclosporine).
Care Phases:
Pretransplantation.
During treatment.
Post-transplantation care for recipients and donors.
Focus on maintaining tissue integrity: stomatitis, skin integrity, alopecia, malignant lesions.
Addressing nutritional impairment and cancer-related anorexia-cachexia syndrome.
Strategies to relieve pain and manage fatigue.
Infection and septic shock.
Risk of bleeding and hemorrhage.
Importance of early referral for comprehensive care in terminal illness.
Focus on quality of life and palliation of symptoms, including psychosocial support.
Understand basic cancer terminologies, tumor staging, and differences between benign and malignant tumors.